Maynard Um
-
-
-
-
-
-
-
Increasing unusual call OMER TRIP SPCE PURR XP
-
-
-
-
-
-
-
Omeros begins commercial sales of YARTEMLEA for rare blood disorder
-
-
-
-
-
-
-
Omeros publishes study showing survival benefits of narsoplimab treatment
-
-
-
-
-
-
-
Omeros (OMER) Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
-
-
-
-
-
-
-
Omeros (OMER) Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
-
-
-
-
-
-
-
Omeros (OMER) Provides Update on Progress Toward BLA Resubmission
-
-
-
416,461 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

